$EDSA When investors are willing to place a valuation of $400M on NRXP that is: 1) Getting sued by their collaboration partner 2) Never proven efficacy at a 28 day mortality endpoint in critical COVID patients 3) Has a horrendous balance sheet with obvious big share dilution coming down the pipe This makes me pretty comfortable with Edesa :)
3
5
5 Likes